Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/165918UNIVERSAL ANTI-CORONAVIRUS CONSERVATIVE EPITOPE IGY AND BROAD-SPECTRUM ANTI-NOVEL CORONAVIRUS IGY AND COMPOSITE ANTIBODY
WO 11.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/080581 Applicant SHENZHEN JASON INTELLIGENT BIOENGINEERING LTD. Inventor PAAU, Shing
Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention is a method for preparing the universal anti-coronavirus conservative epitope IgY and the broad-spectrum anti-variation novel coronavirus IgY antibody and an anti-mutation novel coronavirus IgY antibody and the combined antibody. Furthermore, the IgY and the composite IgY and the combined antibody can bind to a coronavirus universal conservative epitope and an antigen epitope with strong conservation, to achieve a broad-spectrum neutralizing virus effect, and the problems of coronavirus and novel coronavirus being prone to variation and immune escape and treating an asymptomatic patient are solved. Further provided in the present invention are a central air conditioner atomizing disinfectant and outer packaging disinfectant and an aerosol inhalation, spray, oral spray, nasal spray, nasal drops, eye drops, air disinfectant, hand sanitizer, powder, tablet, mouth lozenge, oral liquid and capsule made from the IgY and the composite IgY, which are used in drugs, disinfection products, health-care products and medical devices for preventing and treating coronavirus and novel coronavirus infections.
2.WO/2022/170126COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF
WO 11.08.2022
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2022/015357 Applicant ADAGIO THERAPEUTICS, INC. Inventor WALKER, Laura
The present disclosure is directed to antibodies and antigen binding fragments thereof having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
3.WO/2022/161346ANTIBODY AGAINST SARS-COV-2
WO 04.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/073733 Applicant BIODURO (JIANGSU) CO., LTD. Inventor LI, Xiang
A nanobody capable of specifically recognizing SARS-CoV-2 spike glycoprotein RBD is provided, and the nanobody comprises a CDR having an amino acid sequence selected from at least one of the following or at least 95%identical to the following: a CDR sequence of a heavy chain variable region: SEQ ID NO: 1~21.
4.WO/2022/162202TREATMENT AND/OR PREVENTION OF AN INFECTION BY MONO/DIVALENT AND POLYVALENT ANTIGEN PARTICLE-MEDIATED IMMUNE RESPONSES
WO 04.08.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2022/052147 Applicant VACCINVENT GMBH Inventor JUMAA-WEINACHT, Hassan
The invention pertains to means and methods for the targeted modulation of immune responses by bringing into contact a B-cell with mono/divalent antigen particles and/or polyvalent antigen particles. The targeted modulation of B-cell immunity can be used in the therapy of infections. The invention is predicated on the observation that the combination of polyvalent antigenic structures and mono/divalent antigenic structures harbour the ability to potentiate immune responses against antigens.
5.WO/2022/161472SARS-COV-2 BINDING MOLECULES AND USES THEREOF
WO 04.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/074735 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides single domain antibodies that bind to SARS-CoV-2 S1, and fusion proteins comprising same. Pharmaceutical compositions, kits and methods of preventing or treating a disease or disorder such as a respiratory disease are also provided.
6.WO/2022/161491NEUTRALIZING ANTIBODY FOR SARS-COV-2 VIRUS
WO 04.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/074998 Applicant INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Inventor TANG, Hong
Provided in the present invention is a monoclonal antibody with a neutralizing effect on the SARS-CoV-2 virus. Meanwhile, provided in the present invention is a method for detecting the neutralizing capacity and the binding capacity of the antibody. The antibody of the present invention is simple in preparation process and high in product purity, is a fully human IgG antibody, and has a relatively strong neutralizing effect on the SARS-CoV-2 virus.
7.2603166Therapeutic and Diagnostic Agents and Uses Thereof
GB 03.08.2022
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No 202101228 Applicant THELPER AS Inventor KATJA VETVIK
A binding molecule such as an antibody or CAR having specificity to an epitope within extracellular domain 3 (ECD3) of a unique short 28 (US28) protein of human cytomegalovirus (HCMV), wherein ECD3 of the US28 protein comprises an amino acid sequence presented in the US28 protein at positions corresponding to positions 167 to 183 of the US28 protein encoded by HCMV as set forth in SEQ ID NO:5. Further disclosed is a peptide or polypeptide comprising, consisting essentially of, or consisting of, the sequence TKKNNQCMTDYDYLEVS (SEQ ID NO: 6), or comprising the sequence of an immunogenic fragment of SEQ ID NO: 6; or a peptide or polypeptide comprising, consisting essentially of, or consisting of, the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7), or comprising the sequence of an immunogenic fragment of SEQ ID NO: 7; wherein said peptide or polypeptide is not the US28 protein. Further disclosed are methods of screening for binding molecules which have binding specificity to an epitope within ECD3 of a US28 protein of HCMV.
8.WO/2022/156653EXPRESSION VECTOR FOR ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES
WO 28.07.2022
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
Appl.No PCT/CN2022/072439 Applicant NEWSOARA BIOPHARMA CO., LTD. Inventor LI, Yuannian
Provided are recombinant expression vectors expressing a novel neutralizing antibody against SARS-COV-2, or the antigen binding fragments thereof. Pharmaceutical compositions and kits comprising the same, and the uses thereof are also provided.
9.WO/2022/157774ANTIBODIES, PEPTIDES AND COMBINATIONS OF SAME FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION
WO 28.07.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IL2022/050088 Applicant YEDA RESEARCH AND DEVELOPMENT CO. LTD. Inventor SHULMAN, Ziv
A composition comprising at least one antigenic determinant of Coronavirus and at least one antibody comprising an antigen binding domain which binds said at least one antigenic determinant of Coronavirus is provided. Also provides uses of such compositions.
10.WO/2022/159685SARS-COV-2 CORONAVIRUS ANTIBODIES AND USES THEREOF
WO 28.07.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/013291 Applicant VANDERBILT UNIVERSITY Inventor GEORGIEV, Ivelin Stefanov
The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.